News Briefs

05/11/2022

Amber Specialty Pharmacy added to Eisai’s Lenvima network

Image
Injectables

Amber Specialty Pharmacy, a subsidiary of Hy-Vee, will begin dispensing Eisai’s Lenvima (lenvatinib).

Used by itself, Lenvima treats differentiated thyroid cancer when it can no longer be treated with radioactive iodine and hepatocellular carcinoma when it cannot be removed by surgery.

Lenvima is used with other medications to treat additional types of cancers, including advanced renal cell carcinoma and advanced endometrial carcinoma.

Amber Specialty Pharmacy’s high-touch service model will support patients, caregivers and oncology specialists throughout the country. Its Oncology Center of Excellence provides an enhanced level of care throughout a patient’s treatment journey, the company said.

"Supporting patients who are navigating a cancer diagnosis is one of the most important things we do,” said Kristin Williams, president of Amber Specialty Pharmacy. “We are honored Eisai recognizes the value our whole-health approach offers oncology patients. From reducing or eliminating financial barriers to one-on-one counseling with our registered dietitian — and everything in between — oncology professionals can trust Amber Specialty Pharmacy to make sure patients have the medicine and support they deserve.”

 

Advertisement
05/11/2022

Aurobindo receives FDA OK for generic Sabril

Image
White pills spilling out of a medicine bottle

The Food and Drug Administration has given the green light for Aurobindo’s vigabatrin tablets in a dosage strength of 500 mg.

The medication is the generic of Lundbeck’s Sabril, which is indicated as adjunctive therapy for adults and pediatric patients aged 2 years old and older with refractory complex partial seizures.

Vigabatrin tablets had a market value of roughly $138 million for the 12 months ending March 2022, according to IQVIA.

05/11/2022

Camber launches generic Reyataz

Image
camber atazanavir

Camber is introducing atazanavir capsules.

The medication is the generic of Bristol Myers Squibb's Reyataz.

It is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and in pediatric patients aged 6 years old and older weighing at least 33 lbs.

Camber’s atazanavir capsules are available in 150 mg and 200 mg 60-count bottles and a 300 mg 30-count bottle.

Advertisement
05/11/2022

Elite Pharmaceuticals appoints CFO

Image
new hire employees teaser

Elite Pharmaceuticals, a specialty pharmaceutical company developing and manufacturing niche generic products, is welcoming Robert Chen as its chief financial officer, effective May 16, 2022. Chen succeeds Marc Bregman.

Chen joins Elite with broad experience in financial and operational leadership for life science companies, both private and public, ranging from preclinical development to commercial operations.

The company said that Chen brings with him an extensive and diversified financial leadership background in the areas of financial reporting, including manufacturing, financial and cost accounting, SEC, GAAP, and IFRS, as well as financial planning and analysis.

“Robert is an outstanding addition to our executive team as a seasoned public company CFO with more than 20 years of operational experience," said Nasrat Hakim, president and CEO of Elite. "The board and I are looking forward to working with Robert."

Chen previously served in roles as CFO, vice president of finance and corporate controller primarily in the life sciences sector.

He most recently served as vice president of finance for KBP Biosciences, a clinical-stage biotech start-up. He also had financial positions at Bradley Pharmaceuticals, Novartis, Victory Commercial Management, Medimetriks Pharmaceuticals and Taiho Oncology.

Chen has a bachelor's of science degree in business administration, accounting and a master's degree in accounting from the University of Southern Mississippi. He is a certified public accountant.

05/11/2022

Rice Krispies Treats adds cinnamon sugar variety

Image
Rice Krispies Treats Homestyle Cinnamon Sugar

There’s a new addition to the Rice Krispies Treats family.

The Battle Creek, Mich.-based company released Homestyle Cinnamon Sugar variety, which features fluffy marshmallows, golden butter and a sprinkle of warm cinnamon.

“Whether you’re a busy parent packing lunchboxes or a grown-up kid craving a taste of childhood, fans can enjoy this deliciously sticky, simple snack any time of day and be transported to a homey kitchen in just one bite,” said Heidi Ray, senior director of brand marketing at Kellogg’s portable wholesome snacks. “What’s more, this is the first-ever Cinnamon Sugar flavor for our Rice Krispies Treats brand, and we’re excited to add it to our beloved line of Homestyle bars.”

Rice Krispies Treats Homestyle Cinnamon Sugar is now available at grocery stores nationwide in a pack of six that retails for $3.99 and a pack of 12 for $5.24.

05/10/2022

Endo acquires Nevakar’s injectable product candidates

Image
Injectables

Endo’s subsidiary Endo Ventures has acquired six development-stage, ready-to-use injectable product candidates from Nevakar Injectables.

"These six product candidates that would be used in critical care settings meaningfully expand Endo’s ready-to-use injectable product pipeline," Scott Sims, Endo senior vice president and general manager of injectable solutions and generics, said. "We look forward to further developing and bringing these durable and differentiated products to market — and to the healthcare providers and patients who need them."

The product candidates are in various stages of development, with the first launch expected in 2025. With the acquisition, Endo controls all remaining development, approval, launch and commercialization activities for these product candidates. Endo's Par Sterile Products business will commercialize the products in the United States.

EVL purchased the six product candidates from Nevakar Injectables for a one-time payment of $35 million. The one-time payment is expected to be expensed immediately in the second quarter as acquired in-process research and development costs. This acquisition is separate from Endo's previously announced exclusive licensing agreement with Nevakar.